Overview
U.S. medical device maker's Q1 sales fell 1.3% but beat analyst expectations
Adjusted EPS for Q1 declined yr/yr but beat analyst expectations
Company raised full-year 2026 organic revenue growth outlook to 5.0%-6.5%
Outlook
Conmed raises 2026 organic constant currency revenue growth outlook to 5.0%-6.5%
Company sees 2026 reported revenue at $1.350 bln-$1.375 bln, up from prior $1.345 bln-$1.375 bln
Conmed maintains 2026 adjusted diluted EPS guidance at $4.30-$4.45
Result Drivers
GI PRODUCT EXIT - Co said Q1 sales were reduced by $15.5 mln due to exit of certain gastroenterology products
STRATEGIC FOCUS - Co said it is concentrating resources and investment on higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair
Company press release: ID:nBw6bHbvda
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$317.05 mln
$310.51 mln (6 Analysts)
Q1 Adjusted EPS
Beat
$0.89
$0.82 (6 Analysts)
Q1 EPS
$0.45
Q1 Net Income
$13.83 mln
Q1 Income from Operations
$25.42 mln
Q1 Pretax Profit
$18.36 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Conmed Corp is $43.00, about 16.9% above its April 28 closing price of $36.79
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)